Why is Windlas Biotech falling/rising?

As of 17-Jul, Windlas Biotech Ltd is experiencing a decline in its stock price, currently at 938.50, which reflects a decrease of 6.5 or 0.69%. The stock has underperformed its sector today by 1.11% and has seen a trend reversal after three consecutive days of gains. Although the stock has shown a positive return of 3.08% over the past week and 3.17% over the past month, it has a year-to-date decline of 9.19%. The stock is trading above its 5-day, 20-day, 50-day, and 100-day moving averages but below its 200-day moving average. Additionally, there has been a notable drop in investor participation, with delivery volume falling by 19.26% against the 5-day average.
In the broader market context, while Windlas Biotech has generated a significant return of 30.56% over the past year, it has lagged behind the benchmark Sensex, which has increased by 5.27% year-to-date. The company has a low debt-to-equity ratio and has seen increasing participation from institutional investors, who now hold 12.41% of the company. However, concerns about poor long-term growth, as indicated by a flat operating profit growth rate of 12.19% over the last five years and the lowest cash and cash equivalents recorded at Rs 15.93 crore, may be contributing to the stock's recent decline.